CELL INTELLIGENCE · 肿瘤细胞治疗研究

携带 BLM 突变的 DLBCL 患者在接受 CD19/CD22 双特异性 CAR-T 细胞治疗后发生继发性外周 T 细胞淋巴瘤

Secondary peripheral T-cell lymphoma in a patient with DLBCL harboring BLM mutation following CD19/CD22 bispecific CAR-T cell therapy.

SLC7A11 与 PD-L1 共表达增高与结外自然杀伤 T 细胞淋巴瘤患者不良预后相关

The increased co-expression of SLC7A11 and PD-L1 was associated with poor prognosis in extranodal natural killer T-cell lymphoma patients.

活细胞 Pick-Seq（LiP-Seq）：探究 CAR-T19 治疗后的超罕见套细胞淋巴瘤持续细胞

Live-cell Pick-Seq (LiP-Seq): Interrogating ultra-rare mantle cell lymphoma persistent cells after CART19 therapy.

CAR-T 细胞治疗在肿瘤免疫治疗中的应用——生物学、临床成功与新兴挑战：综述

CAR-T cell therapy in cancer immunotherapy - Biology, clinical successes, and emerging challenges: A review.

复发/难治性 B 细胞非霍奇金淋巴瘤中 CD19/20 CAR-T 疗法的临床结局与空间转录组图谱

Clinical outcomes and spatial transcriptomic profiles of CD19/20 CAR-T therapy in relapsed or refractory B-cell non-Hodgkin's lymphoma.

双特异性 CD19/20 CAR-T 疗法产生了持久的临床活性，且毒性可控。

B 细胞恶性肿瘤蛋白质组图谱鉴定套细胞淋巴瘤蛋白特征

Proteome landscape of B-cell malignancies identifies mantle cell lymphoma protein signature.

CD19/CD22 bispecific CAR-T（CD19CAR-T 细胞）治疗大 B 细胞淋巴瘤：II 期临床试验

CD19/ CD22 Bispecific CAR-T Cell Therapy for Relapsed/ Refractory Large B-cell Lymphoma

这是一项 II 期注册临床试验，评估 CD19CAR-T 细胞治疗大 B 细胞淋巴瘤的疗效与安全性。当前状态：进行中（不再招募）。计划入组 100 例。试验地点：中国 · 北京（共 1 个中心，其中中国 1 个）。登记号：NCT07461831。

Axicabtagene ciloleucel 联合利妥昔单抗治疗难治性大 B 细胞淋巴瘤：2 期单臂 ZUMA-14 试验

Axicabtagene ciloleucel in combination with rituximab for refractory large B cell lymphoma: the phase 2, single-arm ZUMA-14 trial.

用于复发/难治性弥漫大 B 细胞淋巴瘤患者的独特环状结构 CD19/CD22 双特异性 CAR-T 细胞治疗：一项观察性研究

Unique loop-structured CD19/CD22 bispecific CAR-T-cell therapy for patients with relapsed/refractory diffuse large B-cell lymphoma: an observational s

CD19/CD22 BS Loop CAR-T 细胞疗法表现出强效的抗淋巴瘤活性，同时解决了设计对两种抗原具有同等效力的 CAR-T 细胞所面临的挑战。

接头 CAR 共表达在淋巴瘤单一及双重抗原丢失后保留 CAR-T 细胞疗效

Co-expression of an adapter CAR retains efficacy of CAR T cells after single and dual antigen loss in lymphoma.